GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Horizon Therapeutics PLC (FRA:HPR) » Definitions » EV-to-Revenue

Horizon Therapeutics (FRA:HPR) EV-to-Revenue : 7.29 (As of Apr. 26, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Horizon Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Horizon Therapeutics's enterprise value is €25,311 Mil. Horizon Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was €3,473 Mil. Therefore, Horizon Therapeutics's EV-to-Revenue for today is 7.29.

The historical rank and industry rank for Horizon Therapeutics's EV-to-Revenue or its related term are showing as below:

FRA:HPR' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.42   Med: 5.29   Max: 15.67
Current: 7.32

During the past 13 years, the highest EV-to-Revenue of Horizon Therapeutics was 15.67. The lowest was 0.42. And the median was 5.29.

FRA:HPR's EV-to-Revenue is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.29 vs FRA:HPR: 7.32

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-26), Horizon Therapeutics's stock price is €110.20. Horizon Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was €14.84. Therefore, Horizon Therapeutics's PS Ratio for today is 7.43.


Horizon Therapeutics EV-to-Revenue Historical Data

The historical data trend for Horizon Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Horizon Therapeutics EV-to-Revenue Chart

Horizon Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.50 5.44 6.86 7.90 7.18

Horizon Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.99 3.93 7.18 7.04 6.48

Competitive Comparison of Horizon Therapeutics's EV-to-Revenue

For the Drug Manufacturers - General subindustry, Horizon Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Horizon Therapeutics's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Horizon Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Horizon Therapeutics's EV-to-Revenue falls into.



Horizon Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Horizon Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=25311.036/3473.228
=7.29

Horizon Therapeutics's current Enterprise Value is €25,311 Mil.
Horizon Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €3,473 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Horizon Therapeutics  (FRA:HPR) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Horizon Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=110.20/14.837
=7.43

Horizon Therapeutics's share price for today is €110.20.
Horizon Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €14.84.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Horizon Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Horizon Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Horizon Therapeutics (FRA:HPR) Business Description

Traded in Other Exchanges
N/A
Address
70 St. Stephen’s Green, Dublin, IRL, D02 E2X4
Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others.